Key Takeaways
- Erin Wright of Morgan Stanley maintains Buy recommendation on UNH, setting price objective at $375
- UNH designated as Wright’s leading selection amid enhanced optimism in managed care sector
- Medicare Advantage final rate notification provided improved transparency for 2026 payment structures
- First-quarter results scheduled for April 21; analysts project EPS of $6.60 versus prior year’s $7.20
- Bernstein SocGen maintains Outperform designation with $411 price objective for UNH
Morgan Stanley is expressing strong confidence in UNH ahead of its first-quarter financial disclosure. Erin Wright, the firm’s analyst covering the healthcare sector, reaffirmed her Buy recommendation with a $375 price objective while elevating UnitedHealth to her premier selection within managed care.
UnitedHealth Group Incorporated, UNH
This endorsement arrives following a challenging period for the healthcare giant. Concerns surrounding Medicare Advantage profitability and medical cost inflation have created pressure on UNH shares. Wright now believes these obstacles are beginning to diminish.
A primary catalyst for her strengthened outlook involves the finalized Medicare Advantage rate announcement. This guidance provided enhanced transparency regarding 2026 payment structures and supported projections that UNH can continue advancing MA profitability.
Wright is closely monitoring the transformation underway at Optum Health. Following operational challenges within this division, she observes increasing evidence that the unit is progressing toward recovery.
She additionally highlighted artificial intelligence-powered operational improvements as a developing advantage. While still nascent, Wright believes UnitedHealth’s technology initiatives could yield substantial operational benefits in coming years.
First-Quarter Results Due April 21
UNH will unveil first-quarter performance on Tuesday, April 21. Wright anticipates results largely aligned with expectations, without significant deviations.
Analyst consensus forecasts Q1 revenue reaching $109.52 billion, marginally below the $109.58 billion recorded in the corresponding quarter last year. Earnings per share are projected at $6.60, declining from $7.20 in the year-ago period.
Market participants will scrutinize Medicare Advantage profitability trajectories, medical expense updates, and management commentary regarding Optum Health’s turnaround. Progress on AI-driven efficiencies and full-year guidance will also command attention.
UNH presently trades at $316.40. Based on this valuation, Morgan Stanley’s $375 objective suggests potential appreciation of approximately 18.5%.
Bernstein Expresses Strong Optimism
Bernstein SocGen projects even greater upside potential. Their analyst Lance Wilkes reaffirmed an Outperform rating alongside a $411 price target, characterizing UNH’s current valuation as compelling.
The research house anticipates a sector-wide rebound as Medicare Advantage margins recover from recent lows following rate pressures and competitive exits from the marketplace.
Bernstein also identifies company-specific margin expansion opportunities as UNH discontinues unprofitable MA and Optum Health offerings. The firm forecasts robust earnings growth throughout the next four-year period.
The stock currently carries a P/E multiple of 24. For perspective, the consensus Wall Street price target across 18 Buy ratings and 5 Hold ratings stands at $366.24 — suggesting approximately 15.75% appreciation from present levels.
One notable risk factor: Leerink highlighted that UNH confronts heightened exposure to expanded RADV audit activity conducted by CMS. Sixty contracts representing 92% of its Medicare Advantage enrollment are undergoing examination — a dramatic increase from zero contracts in 2018. These audits commenced processing in April 2025.
UBS recently incorporated UNH into its Global High-Quality Dividend Stock List, recognizing it as a dependable dividend provider.
